Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

REDWOOD CITY, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 2019 H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019, at 4:50 PM BST / 11:50 AM ET, in London, United Kingdom.  A webcast of the presentation will be available here:  http://wsw.com/webcast/hcw4/slno/.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit www.soleno.life.

CONTACT:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578